EMA Authorised: Emtricitabine/Tenofovir disoproxil Mylan (emtricitabine;tenofovir disoproxil maleate) — Mylan Pharmaceuticals Limited

View source ↗

Summary

EMA authorised Emtricitabine/Tenofovir disoproxil Mylan for HIV infections. It provides a fixed-dose combination option for antiretroviral therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Emtricitabine/Tenofovir disoproxil Mylan (emtricitabine; tenofovir disoproxil maleate)

Snippet

Status: Authorised. Therapeutic area: HIV Infections. MAH: Mylan Pharmaceuticals Limited. Decision date: 27/06/2025